Our Services
Medical Information
Helpful Resources
Published on: 9/24/2026
The honeymoon phase of type 1 diabetes is a temporary period soon after diagnosis when remaining beta cells still produce some insulin, causing blood sugar to stabilize and insulin needs to drop, sometimes dramatically. It typically begins within weeks of starting insulin and can last months to a couple of years, but it is not remission or a cure, and insulin requirements rise again as beta cell function fades. There are several factors that affect how long it lasts and how doses should be adjusted, including age, antibody levels, C-peptide results, illness, and hypoglycemia risk, so see below to understand the full picture before changing anything.
If you or your child are noticing unexpectedly low blood sugars, falling insulin needs, or new symptoms like thirst, fatigue, frequent urination, or unexplained weight loss, getting clarity quickly matters because these patterns can signal either a honeymoon period or a problem that needs prompt attention. Take a free, instant, online symptom check to better understand what your symptoms may mean and what steps to take next with your care team.
Last reviewed for medical accuracy: 09/24/2026
When someone is first diagnosed with type 1 diabetes, their pancreas often still produces a small amount of insulin. This early period—usually lasting a few weeks to several months—is known as the honeymoon phase. During this time, blood sugar levels may become easier to control and insulin requirements often decline. Understanding what’s happening can help you or your loved one manage expectations and stay prepared.
Type 1 diabetes is an autoimmune condition where the body’s immune system attacks the insulin-producing beta cells in the pancreas. Yet, at diagnosis:
Over time, the immune attack continues, and insulin production falls. This gradual decline ends the honeymoon phase.
The length of the honeymoon phase varies widely:
No one can predict exactly how long it will last, so close monitoring is key.
During this period, you might notice:
Keep detailed records of blood sugar readings, insulin dosages, meals and activity. This data helps you and your care team fine-tune management.
Even though things may feel easier, staying vigilant is crucial:
Document every dose change and blood sugar reading. This will guide adjustments once the honeymoon period ends.
A common question is “can you reverse type 1 diabetes?” Currently, there is no cure. The honeymoon phase may feel like a temporary reversal, but it does not stop the underlying autoimmune attack. Research is ongoing to:
Until a proven cure is available, management focuses on insulin therapy, lifestyle and monitoring.
Staying on top of symptoms and blood sugar trends helps you navigate both the honeymoon phase and the years ahead. You might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to explore any new or worrying signs. While nothing replaces medical advice, symptom tools can guide your next steps.
Even during a stable honeymoon period, certain situations call for prompt attention:
If you experience life-threatening or serious symptoms at any time, please speak to a doctor or visit the nearest emergency department.
Once the honeymoon phase ends, insulin requirements often rise. A long-term plan includes:
Having a strong support system makes it easier to adjust when insulin needs increase.
Type 1 diabetes is a lifelong condition, but understanding phases like the honeymoon period helps you stay prepared. Speak to your doctor about any changes in symptoms, insulin needs or overall health. Continuous learning and proactive care are your best tools for living well with type 1 diabetes.
(References)
* Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990 Jun;13(6):610-30. doi: 10.2337/diacare.13.6.610. PMID: 2192847.
* Böber E, Dündar B, Büyükgebiz A. Partial remission phase and metabolic control in type 1 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab. 2001 Apr;14(4):435-41. doi: 10.1515/jpem.2001.14.4.435. PMID: 11327378.
* Stamper IJ, Jackson E, Wang X. Phase transitions in pancreatic islet cellular networks and implications for type-1 diabetes. Phys Rev E Stat Nonlin Soft Matter Phys. 2014 Jan;89(1):012719. doi: 10.1103/PhysRevE.89.012719. Epub 2014 Jan 27. PMID: 24580269; PMCID: PMC4172977.
* Pyziak-Skupien A, Bobeff K, Wyka K, Banach K, Malachowska B, Fendler W, Szadkowska A, Mlynarski W, Zmyslowska A. Fetuin-A and Interleukine-8 in Children with the Clinical Remission of Type 1 Diabetes. Iran J Immunol. 2020 Jun;17(2):144-153. doi: 10.22034/iji.2020.82797.1595. PMID: 32602468.
* Quattrin T, Haller MJ, Steck AK, Felner EI, Li Y, Xia Y, Leu JH, Zoka R, Hedrick JA, Rigby MR, Vercruysse F, T1GER Study Investigators. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes. N Engl J Med. 2020 Nov 19;383(21):2007-2017. doi: 10.1056/NEJMoa2006136. PMID: 33207093.
* Nwosu BU. The Theory of Hyperlipidemic Memory of Type 1 Diabetes. Front Endocrinol (Lausanne). 2022;13:819544. doi: 10.3389/fendo.2022.819544. Epub 2022 Mar 31. PMID: 35432186; PMCID: PMC9009047.
* Mittal M, Porchezhian P, Kapoor N. Honeymoon phase in type 1 diabetes mellitus: A window of opportunity for diabetes reversal? World J Clin Cases. 2024 Jan 6;12(1):9-14. doi: 10.12998/wjcc.v12.i1.9. PMID: 38292619; PMCID: PMC10824181.
* Zhong T, Li X, Lei K, Tang R, Deng Q, Love PE, Zhou Z, Zhao B, Li X. TGF-β-mediated crosstalk between TIGIT(+) Tregs and CD226(+)CD8(+) T cells in the progression and remission of type 1 diabetes. Nat Commun. 2024 Oct 15;15(1):8894. doi: 10.1038/s41467-024-53264-8. Epub 2024 Oct 15. PMID: 39406740; PMCID: PMC11480485.
* Gomez-Muñoz L, Perna-Barrull D, Ventura PS, Valls A, Castiello F, Vives-Pi M, Murillo-Vallés M. Identification of Peripheral Blood Endotypes Associated With Age in Pediatric Type 1 Diabetes. Pediatr Diabetes. 2025;2025:5512196. doi: 10.1155/pedi/5512196. Epub 2025 Sep 27. PMID: 41049864; PMCID: PMC12496154.
* Gomez-Muñoz L, Perna-Barrull D, Klein D, Alvarez-Cubela S, Godoy-Tena G, Cook DA, Voto-Bernales CQ, Doke M, Murillo M, Valls A, Pastori RL, Dominguez-Bendala J, Vives-Pi M. miR-30d-5p promotes beta cell recovery and immunomodulation in type 1 diabetes. Front Endocrinol (Lausanne). 2026;17:1838666. doi: 10.3389/fendo.2026.1838666. Epub 2026 Jun 2. PMID: 42375328; PMCID: PMC13311865.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.